Business Wire

Europe’s Most Advanced Weather Satellite Is Now Fully Operational

4.12.2024 15:26:00 EET | Business Wire | Press release

Share

The first of EUMETSAT’s Meteosat Third Generation (MTG) satellites became fully operational today.

MTG-Imager 1 also receives a new name – Meteosat-12 – to mark the occasion.

The two main instruments on board Meteosat-12, the Flexible Combined Imager (FCI) and the Lightning Imager (LI), play a crucial role in enabling meteorological services to help protect lives and livelihoods by providing high-resolution, accurate data for predicting severe weather events.

Data from Meteosat-12’s instruments are now being disseminated to national meteorological services and others for operational use and are expected to have a significant impact on weather forecasting and understanding of our climate.

“MTG is one of the most innovative and complex meteorological satellite systems ever built,” EUMETSAT Director-General Phil Evans said.

“We have been working with our member states’ meteorological services to ensure they can make the best use of the data, which is essential for one of the main challenges they face - the rapid detection and forecasting of severe weather so that citizenry, civil authorities and first responders receive timely warnings.”

“When the full constellation of MTG is in place, it will be possible, for the first time, to observe the full lifecycle of a convective storm, from before clouds begin to form through to detection of lightning strikes.”

Efficient and impactful use of this new data will also be central to the EU-funded Space for Early Warnings in Africa project, implemented with the African Union Commission. Today, Council approved EUMETSAT’s involvement via an agreement with the European Commission. Starting in January 2025, the project will enhance African capacity to access and process Earth observation data, strengthening early warning systems and resilience to severe weather.

In addition to the FCI and LI, Meteosat-12 also carries the Data Collection and Retransmission Service (DCS) and the Geostationary Search and Rescue Relay (GEOSAR) transponder.

The DCS acquires observations and environmental data from ground-based meteorological platforms in its field of view then transmits them to the MTG ground segment. The GEOSAR transponder acquires signals from distress beacons in its field of view and transmits them to rescue services.

An anomaly in a module of the Flexible Combined Imager meant its commissioning phase lasted longer than anticipated when the spacecraft was launched in mid-December 2022.

“A great deal of hard work, dedication and ingenuity went in to overcoming the anomaly while the satellite was already in orbit 36,000km above the Earth,” Evans said. “I pay tribute to the EUMETSAT teams, supported by ESA and the industry, that achieved that feat and enabled us to reach this important milestone today where we are confident of the quality and reliability of the data we are providing to those who need it.”

Note to editors:

About EUMETSAT

EUMETSAT, Europe’s meteorological satellite agency, monitors the weather and climate from space. Based in Darmstadt, Germany, EUMETSAT provides its 30 member states with meteorological imagery and data that are essential for keeping their communities safe and for the benefit of critical sectors of their economies.

EUMETSAT’s 30 member states are: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.

For more information, see the EUMETSAT website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204449728/en/

Contacts

Media Relations EUMETSAT:
Tel: +49 6151 807 7320
Email: press@eumetsat.int
www.eumetsat.int -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.eumetsat.in
t&esheet=54161656&newsitemid=20241204449728&lan=en-US&anchor=www.eumetsat.int&in
dex=3&md5=b5658ad5621c92013fc6ca7c401f9364

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye